EHA 2023 | Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALL
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale and findings of a Phase II study evaluating the safety and efficacy of hyper-CVAD in combination with blinatumomab with or without inotuzumab ozogamicin in patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (Ph- B-ALL). The study reported an 18-month survival of 100% in the hyper-CVAD-blinatumomab-inotuzumab arm, suggesting the addition of inotuzumab is beneficial in this setting. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Astellas: Research Funding; Takeda Oncology: Consultancy, Research Funding; Pfizer: Consultancy; Stemline Therapeutics: Research Funding; AstraZeneca: Consultancy; Amgen: Consultancy, Honoraria.
